Emrok is a next-generation antibiotic that contains levonadifloxacin, developed to treat serious bacterial infections, especially those caused by drug-resistant organisms. It is used in hospitals and clinical settings for conditions that require strong, broad-spectrum antibacterial coverage. Emrok is available in both injectable and oral forms, making it suitable for step-down therapy from hospital to home.

Mechanism of Action:

Levonadifloxacin belongs to the benzoquinolizine class of fluoroquinolone antibiotics. It works by:

• Inhibiting two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are critical for bacterial DNA replication and cell division

• This action disrupts bacterial function and leads to bacterial cell death

• It has strong activity against Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), as well as activity against Gram-negative and atypical pathogens

• It is designed to work even in acidic environments and biofilm-associated infections, which makes it more effective in complex infections

  Uses:

  Emrok is primarily used to manage serious infections that are difficult to treat with standard antibiotics:

  • Acute bacterial skin and skin structure infections

  • Diabetic foot infections, including those with MRSA

  • Community-acquired and hospital-acquired pneumonia

  • Complicated respiratory tract infections

  • Other multidrug-resistant infections as per the clinician’s guidance

    Adverse Effects:

    Emrok is generally well-tolerated, but like all antibiotics, it may cause some side effects.

    Common side effects:

    • Nausea

    • Vomiting

    • Headache

    • Diarrhoea

    • Local pain or swelling at the injection site